IL129143A0 - Insulin c-peptides - Google Patents

Insulin c-peptides

Info

Publication number: IL129143A0
Authority: IL; Israel
Prior art keywords: peptides; atpase activity; fragment; sequence; insulin
Prior art date: 1996-09-27

Application number

IL12914397A

Other languages

English (en)

Original Assignee

Creative Peptides Sweden Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-27

Filing date

1997-09-26

Publication date

2000-02-17

1997-09-26 Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab

2000-02-17 Publication of IL129143A0 publication Critical patent/IL129143A0/xx

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 4
102000004196 processed proteins & peptides Human genes 0.000 abstract 4
108091006112 ATPases Proteins 0.000 abstract 3
102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
239000012634 fragment Substances 0.000 abstract 3
208000002249 Diabetes Complications Diseases 0.000 abstract 2
108010075254 C-Peptide Proteins 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000003592 biomimetic effect Effects 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
210000002950 fibroblast Anatomy 0.000 abstract 1
108010038088 glutamyl-glycyl-seryl-leucyl-glutamine Proteins 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
150000002894 organic compounds Chemical class 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
210000005233 tubule cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

IL12914397A 1996-09-27 1997-09-26 Insulin c-peptides IL129143A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9603533A SE520392C2 (sv)	1996-09-27	1996-09-27	Specifika peptider för behandling av diabetes mellitus
PCT/GB1997/002627 WO1998013384A1 (en)	1996-09-27	1997-09-26	Insulin c-peptides

Publications (1)

Publication Number	Publication Date
IL129143A0 true IL129143A0 (en)	2000-02-17

Family

ID=20404052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12914397A IL129143A0 (en)	1996-09-27	1997-09-26	Insulin c-peptides

Country Status (24)

Country	Link
US (1)	US6610649B2 (cs)
EP (1)	EP0938503B1 (cs)
JP (1)	JP2001500893A (cs)
KR (1)	KR20000048643A (cs)
AT (1)	ATE347562T1 (cs)
AU (1)	AU741901B2 (cs)
BG (1)	BG103362A (cs)
BR (1)	BR9711573A (cs)
CA (1)	CA2266416C (cs)
CZ (1)	CZ108599A3 (cs)
DE (1)	DE69737065T2 (cs)
DK (1)	DK0938503T3 (cs)
ES (1)	ES2278394T3 (cs)
HU (1)	HUP0000432A3 (cs)
IL (1)	IL129143A0 (cs)
IS (1)	IS5008A (cs)
NO (1)	NO991483L (cs)
NZ (1)	NZ335231A (cs)
PL (1)	PL332494A1 (cs)
RU (1)	RU2206336C2 (cs)
SE (1)	SE520392C2 (cs)
SK (1)	SK39499A3 (cs)
TR (1)	TR199900694T2 (cs)
WO (1)	WO1998013384A1 (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0022342D0 (en) *	2000-09-12	2000-10-25	Creative Peptides Sweden Ab	Reduction of the electrocardiographic QT interval
DE10055857A1 (de) *	2000-11-10	2002-08-22	Creative Peptides Sweden Ab Dj	Neue pharmazeutische Depotformulierung
US20030198666A1 (en) *	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
NZ541058A (en) *	2003-01-06	2008-06-30	Emisphere Tech Inc	Night-time oral insulin therapy
US20050026826A1 (en) *	2003-01-17	2005-02-03	Margarethe Hoenig	Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en)	2004-03-05	2005-09-15	Emisphere Technologies, Inc.	Oral insulin therapies and protocol
GB0323979D0 (en)	2003-10-13	2003-11-19	Creative Peptides Sweden Ab	Therapeutic applications for c-peptide
US7557081B2 (en) *	2004-05-27	2009-07-07	Essential Skincare, Llc	Alpha-1-acid glycoprotein for the treatment of diabetes
US7833513B2 (en)	2004-12-03	2010-11-16	Rhode Island Hospital	Treatment of Alzheimer's Disease
GB0601950D0 (en) *	2006-01-31	2006-03-15	Creative Peptides Sweden Ab	Compositions and methods of treating diabetes
US9505823B2 (en) *	2006-08-07	2016-11-29	TEV A Biopharmaceuticals USA, Inc.	Albumin-insulin fusion proteins
RU2010114049A (ru) *	2007-09-11	2011-10-20	Мондобайотек Лабораториз Аг (Li)	Cgrp в качестве терапевтического средства
GB0723250D0 (en) *	2007-11-28	2008-01-09	Univ Leeds	Compositions and methods for reducing macrovascular complications in diabetic patients
US20110165112A1 (en) *	2008-09-19	2011-07-07	Nektar Therapeutics	Polymer conjugates of c-peptides
EP2898900B1 (en)	2008-09-19	2017-11-15	Nektar Therapeutics	Polymer conjugates of ziconotide
US8410049B2 (en) *	2009-10-28	2013-04-02	Cebix	Methods and kits for preventing hypoglycemia
NZ603399A (en)	2010-05-17	2014-09-26	Cebix Inc	Pegylated c-peptide
AU2012214283B2 (en)	2011-02-11	2016-01-28	The Regents Of The University Of Michigan	Tripeptide compositions and methods for treatment of diabetes
WO2013075117A2 (en)	2011-11-17	2013-05-23	John Wahren	Pegylated c-peptide
RU2522897C1 (ru) *	2013-04-16	2014-07-20	Закрытое акционерное общество "ФАРМ-ХОЛДИНГ"	Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) *	2014-12-30	2016-11-16	건국대학교 산학협력단	프로인슐린의 면역학적 용도
CN104888201B (zh) *	2015-06-29	2018-04-27	齐锦生	用于防治糖尿病及其慢性并发症的肽类药物
AU2018216033B2 (en)	2017-02-06	2021-10-07	Biotempt B.V.	Peptide modulators of the interaction between human C-peptide and human elastin receptor for therapeutic use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU166913B (cs) *	1972-05-15	1975-06-28
JPS5210872B2 (cs)	1973-07-14	1977-03-26
JPS55105653A (en) *	1978-10-02	1980-08-13	Shionogi & Co Ltd	Tyrosyl c-peptides
CH650679A5 (de)	1981-08-27	1985-08-15	Lilly Co Eli	Gegen diabetes mellitus wirksames pharmazeutisches mittel.
US4652548A (en) *	1981-08-27	1987-03-24	Eli Lilly And Company	Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
DE3326473A1 (de)	1983-07-22	1985-01-31	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) *	1984-06-14	1986-04-08	Eli Lilly And Company	Anti-diabetic compounds
US5104854A (en)	1989-02-01	1992-04-14	Washington University	Antiviral peptides
PT93057B (pt)	1989-02-09	1995-12-29	Lilly Co Eli	Processo para a preparacao de analogos da insulina
US5364757A (en)	1990-05-21	1994-11-15	Administrators Of The Tulane Educational Fund	Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) *	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja)	1992-03-27	1993-10-19	Hoechst Japan Ltd	骨形成作用を有する新規な蛋白質およびその製造法
CA2117904C (en)	1992-04-13	2004-06-22	John B. Harley	Methods and reagents for diagnosis of autoantibodies
WO1994025071A1 (en)	1993-05-05	1994-11-10	Keith Rose	Polyoxime compounds and their preparation
AT400723B (de)	1993-08-27	1996-03-25	Biomay Prod & Handel	Rekombinante alternaria alternata allergene
DK0788512T3 (da)	1994-07-08	1999-10-11	Dartmouth College	Proinsulinpeptidforbindelser til detektion og behandling af Type I-diabetes
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en)	1994-11-03	1994-12-21	Univ Dundee	Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en)	1995-05-05	1995-06-28	Smithkline Beecham Plc	Novel compounds
WO1997033909A2 (en)	1996-03-15	1997-09-18	Corixa Corporation	Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US6150500A (en)	1996-07-12	2000-11-21	Salerno; John C.	Activators of endothelial nitric oxide synthase

1996
- 1996-09-27 SE SE9603533A patent/SE520392C2/sv not_active IP Right Cessation
1997
- 1997-09-26 IL IL12914397A patent/IL129143A0/xx unknown
- 1997-09-26 CZ CZ991085A patent/CZ108599A3/cs unknown
- 1997-09-26 CA CA002266416A patent/CA2266416C/en not_active Expired - Fee Related
- 1997-09-26 EP EP97942119A patent/EP0938503B1/en not_active Expired - Lifetime
- 1997-09-26 BR BR9711573-8A patent/BR9711573A/pt not_active Application Discontinuation
- 1997-09-26 SK SK394-99A patent/SK39499A3/sk unknown
- 1997-09-26 KR KR1019990702585A patent/KR20000048643A/ko not_active Withdrawn
- 1997-09-26 DK DK97942119T patent/DK0938503T3/da active
- 1997-09-26 AT AT97942119T patent/ATE347562T1/de not_active IP Right Cessation
- 1997-09-26 PL PL97332494A patent/PL332494A1/xx unknown
- 1997-09-26 RU RU99108434/14A patent/RU2206336C2/ru not_active IP Right Cessation
- 1997-09-26 NZ NZ335231A patent/NZ335231A/xx unknown
- 1997-09-26 WO PCT/GB1997/002627 patent/WO1998013384A1/en not_active Ceased
- 1997-09-26 HU HU0000432A patent/HUP0000432A3/hu unknown
- 1997-09-26 TR TR1999/00694T patent/TR199900694T2/xx unknown
- 1997-09-26 JP JP10515410A patent/JP2001500893A/ja not_active Ceased
- 1997-09-26 DE DE69737065T patent/DE69737065T2/de not_active Expired - Lifetime
- 1997-09-26 US US09/269,439 patent/US6610649B2/en not_active Expired - Fee Related
- 1997-09-26 ES ES97942119T patent/ES2278394T3/es not_active Expired - Lifetime
- 1997-09-26 AU AU43915/97A patent/AU741901B2/en not_active Ceased
1999
- 1999-03-23 IS IS5008A patent/IS5008A/is unknown
- 1999-03-26 NO NO991483A patent/NO991483L/no not_active Application Discontinuation
- 1999-04-27 BG BG103362A patent/BG103362A/xx unknown

Also Published As

Publication number	Publication date
DE69737065D1 (en)	2007-01-18
SE520392C2 (sv)	2003-07-01
ES2278394T3 (es)	2007-08-01
DK0938503T3 (da)	2007-04-10
HUP0000432A2 (hu)	2000-08-28
HUP0000432A3 (en)	2000-10-30
JP2001500893A (ja)	2001-01-23
RU2206336C2 (ru)	2003-06-20
US6610649B2 (en)	2003-08-26
NO991483L (no)	1999-05-18
CZ108599A3 (cs)	1999-08-11
NO991483D0 (no)	1999-03-26
CA2266416A1 (en)	1998-04-02
AU741901B2 (en)	2001-12-13
EP0938503B1 (en)	2006-12-06
EP0938503A1 (en)	1999-09-01
PL332494A1 (en)	1999-09-13
SE9603533L (sv)	1998-03-28
ATE347562T1 (de)	2006-12-15
TR199900694T2 (xx)	1999-06-21
DE69737065T2 (de)	2007-06-28
BG103362A (en)	2000-05-31
BR9711573A (pt)	2000-01-18
AU4391597A (en)	1998-04-17
NZ335231A (en)	2000-11-24
IS5008A (is)	1999-03-23
KR20000048643A (ko)	2000-07-25
CA2266416C (en)	2008-04-29
SE9603533D0 (sv)	1996-09-27
SK39499A3 (en)	1999-10-08
WO1998013384A1 (en)	1998-04-02
US20020107175A1 (en)	2002-08-08

Publication	Publication Date	Title
DE69737065D1 (en)	2007-01-18	Insulin c-peptide
DE69531889D1 (de)	2003-11-13	Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
NL300432I2 (en)	2010-04-01	Pharmaceutical composition comprising pioglitazoneand glimepiride for use in treatment of diabetes.
EP0919242A3 (en)	2003-01-02	Method for administering acylated insulin
TR200100600T2 (tr)	2001-07-23	İnsülinotropik peptitlerin kullanımı.
PT915910E (pt)	2006-05-31	Analogos de exendina, processos para a sua preparacao e medicamentos que os contem
TR199802423T2 (xx)	1999-02-22	Konsantre antikor terkibi.
PT1171465E (pt)	2004-12-31	Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
TR199902033T2 (xx)	2000-02-21	Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
HUP0100928A3 (en)	2001-11-28	Methods for treatment of diabetes using peptide analogues of insulin
BG101392A (en)	1997-10-31	Method of treating diabetes mellitus using kgf
IS4510A (is)	1997-06-19	Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
BR9105783A (pt)	1992-07-21	Polipeptidio,processo para o tratamento em vidro de neuronios e composicoes celular e farmaceutica
WO1999064598A3 (de)	2000-03-16	Neue insulinanaloga mit erhöhter zinkbindung
AU2668400A (en)	2000-08-25	Human antibiotic proteins
WO2003072126A3 (de)	2004-01-15	Verwendung eines fibroblastenwachstumsfaktor-bindeproteins zur behandlung und diagnose von diabetischen wundheilungsstörungen
EP0967276A3 (en)	2001-04-18	Anti-tumor agent comprising salmosin
IL134137A0 (en)	2001-04-30	Methods for diagnosis and theraphy of autoimmune diseases, such as insulin dependent diabetes mellitus, involving retroviral superantigens
WO2002045735A3 (en)	2003-01-03	Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus
ATE206306T1 (de)	2001-10-15	Verwendung von 9,10-secocholesta-5,7,10(19)-trien-1,3-ol (alfacalcidol)
WO2003099863A3 (en)	2004-02-19	Resistin binding proteins, their preparation and use
AU6723898A (en)	1998-09-18	Composition for treating tanned leather, and its preparation
DK1340507T3 (da)	2005-02-28	Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser
KR950032278U (ko)	1995-12-14	인슐린 패치용 피부 처리기
BR9703451A (pt)	1998-12-22	Composto natural para tratamento de diabete câncer e etc